Johnson & Johnson (JNJ) stock forecast & analysis
247.82
NYSE · USDDelayed by 20 minutes
Down: -15.91, -6.0%
1 analysis
Latest analysis: · verdict locked
- Open
- 254.56
- Previous close
- 263.73
- Day range
- 245.19 – 256.18
- 52-week range
- 184.66 – 281.07
- Volume (shares)
- 7.93M
- Net assets
- Not available
- Expense ratio
- Not available
- Shares outstanding
- 2.41B
- P/E ratio
- 28.72
- Dividend yield
- 2.03%
- Beta
- 0.21
- Market cap
- 597.22B
Market Scanner’s AI analysis of Johnson & Johnson (JNJ), updated October 2026: Johnson & Johnson's Q3 earnings report and MedTech slowdown overshadowed raised full-year outlook, leading to stock decline.
This page is the public summary. A signed-in user can run a fresh five-stage AI analysis of Johnson & Johnson (JNJ) and read the full verdict with the bull and bear debate behind it — using Market Scanner tokens, or their own OpenAI or Anthropic key.
Summary
Johnson & Johnson's Q3 earnings report and MedTech slowdown overshadowed raised full-year outlook, leading to stock decline.
Recent analyses covered Johnson & Johnson's (JNJ) Q3 earnings report, which revealed a slowdown in its MedTech business despite an increased full-year outlook. The company's stock experienced a decline following the report, influenced by mixed performance across its segments and broader market sentiment. Financial metrics such as revenue growth, profitability, and valuation multiples were also examined.
JNJ news & sentiment
News reports indicated a stock decline for Johnson & Johnson following its Q3 earnings, influenced by a slowdown in its MedTech business and a broader market downturn in the healthcare sector. Social media discussions were not covered in the provided notes.
JNJ technical picture
The stock's price action showed short-term downward momentum, trading below its 10-day and 50-day moving averages but remaining above its 200-day moving average. Momentum indicators suggested the stock was approaching oversold territory with weak buying pressure and bearish momentum, reinforced by its position near the lower Bollinger Band.
Fundamentals
Johnson & Johnson's TTM revenue showed positive year-over-year growth, though quarterly earnings experienced a year-over-year decline. The company's profitability metrics were noted, alongside its dividend yield and liquidity ratios. Valuation was assessed through P/E ratios, and total debt levels were also covered.
Factors discussed — upside
- Year-over-year quarterly revenue growth of 6.6%
- Profit margin of 21.5%
- Return on Equity (TTM) of 25.7%
- Dividend yield of 2.03%
- Stock price above its 200-day SMA of $243.41
Factors discussed — risks
- MedTech business growth decreased from 7.7% to 2.5%
- Quarterly earnings growth year-over-year was -0.9%
- Stock trading below its 10-day EMA and 50-day SMA
- MACD below zero suggesting bearish momentum
- Took a $5.5 billion charge related to talc claims
- MedTech performance
- Financial results
- Market sentiment
- Valuation
Summary updated .
JNJ technical indicators
Common technical indicators for JNJ, computed from its daily closing prices.
| Indicator | Value | Reading |
|---|---|---|
| 50-day simple moving average | 265.35 | Price below |
| 10-day exponential moving average | 258.53 | Price below |
| Relative strength index (14-day) | 33.89 | Neutral |
| MACD line (12/26/9) | -3.1196 | Below its signal line |
| Bollinger bands (20-day, 2σ) | 249.51 – 277.68 | Price below the lower band |
Analyses
Recent JNJ.US analyses are locked — sign in to read them or generate a fresh one.
Locked
Unlock in the library — 1 newer report
Sign in to unlock the 2026-10-13 JNJ.US analysis
Get the verdict — free
Frequently asked questions
- What is the bull case for Johnson & Johnson?
- The bull case for Johnson & Johnson centers on its consistent year-over-year revenue growth and strong profitability metrics, including a healthy profit margin and high Return on Equity. The company also offers a notable dividend yield, and its stock price remains above a key long-term support level.
- What are the risks for Johnson & Johnson?
- Risks for Johnson & Johnson include a recent slowdown in the MedTech business, which saw growth decelerate significantly, and negative year-over-year quarterly earnings growth. The stock is also trading below its short- and medium-term moving averages, indicating downward momentum, and the company has incurred a substantial charge related to talc claims.
- Is Johnson & Johnson bullish or bearish?
- Recent AI analyses of Johnson & Johnson examined factors on both sides. Discussed upside: The bull case for Johnson & Johnson centers on its consistent year-over-year revenue growth and strong profitability metrics, including a healthy profit margin and high Return on Equity. The company also offers a notable dividend yield, and its stock price remains above a key long-term support level. Discussed risks: Risks for Johnson & Johnson include a recent slowdown in the MedTech business, which saw growth decelerate significantly, and negative year-over-year quarterly earnings growth. The stock is also trading below its short- and medium-term moving averages, indicating downward momentum, and the company has incurred a substantial charge related to talc claims. These are descriptive observations, not a recommendation.
- What is the latest sentiment on Johnson & Johnson?
- News reports indicated a stock decline for Johnson & Johnson following its Q3 earnings, influenced by a slowdown in its MedTech business and a broader market downturn in the healthcare sector. Social media discussions were not covered in the provided notes.
- How does Market Scanner analyse Johnson & Johnson?
- Every analysis of Johnson & Johnson runs the same five stages: four analysts read the market independently, a bull and a bear debate what they found, one agent turns the ruling into a position, three risk perspectives stress-test it, and a final agent writes the report. Market Scanner publishes what each stage does, with figures computed from the analyses on the platform rather than written in by hand.Read the methodology
What is the bull case for Johnson & Johnson?
The bull case for Johnson & Johnson centers on its consistent year-over-year revenue growth and strong profitability metrics, including a healthy profit margin and high Return on Equity. The company also offers a notable dividend yield, and its stock price remains above a key long-term support level.
What are the risks for Johnson & Johnson?
Risks for Johnson & Johnson include a recent slowdown in the MedTech business, which saw growth decelerate significantly, and negative year-over-year quarterly earnings growth. The stock is also trading below its short- and medium-term moving averages, indicating downward momentum, and the company has incurred a substantial charge related to talc claims.
Is Johnson & Johnson bullish or bearish?
Recent AI analyses of Johnson & Johnson examined factors on both sides. Discussed upside: The bull case for Johnson & Johnson centers on its consistent year-over-year revenue growth and strong profitability metrics, including a healthy profit margin and high Return on Equity. The company also offers a notable dividend yield, and its stock price remains above a key long-term support level. Discussed risks: Risks for Johnson & Johnson include a recent slowdown in the MedTech business, which saw growth decelerate significantly, and negative year-over-year quarterly earnings growth. The stock is also trading below its short- and medium-term moving averages, indicating downward momentum, and the company has incurred a substantial charge related to talc claims. These are descriptive observations, not a recommendation.
What is the latest sentiment on Johnson & Johnson?
News reports indicated a stock decline for Johnson & Johnson following its Q3 earnings, influenced by a slowdown in its MedTech business and a broader market downturn in the healthcare sector. Social media discussions were not covered in the provided notes.
How does Market Scanner analyse Johnson & Johnson?
Every analysis of Johnson & Johnson runs the same five stages: four analysts read the market independently, a bull and a bear debate what they found, one agent turns the ruling into a position, three risk perspectives stress-test it, and a final agent writes the report. Market Scanner publishes what each stage does, with figures computed from the analyses on the platform rather than written in by hand.
Read the methodology- Bundles used
- gemini-low-v2
Run a fresh JNJ.US analysis
Configure the ticker, model bundle and debate depth here — you only sign in at the end, and everything you picked comes with you.